Regeneron Director George L. Sing Files Form 144 for $20.38M Share Sale

Executive Summary

On November 2, 2026, George L. Sing, a member of the Board of Directors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), filed a Form 144 notice disclosing the intent to sell 21,129 shares of common stock through Morgan Stanley Smith Barney LLC. The proposed transaction carries an estimated market value of $20,376,359.76, reflecting an implied price per share of approximately $964.38.

Transaction Details

• Filer: George L. Sing (Director)
• Shares Intended for Sale: 21,129
• Aggregate Market Value: $20,376,359.76
• Approximate Date of Sale: November 2, 2026
• Securities Exchange: NASDAQ
• Shares Outstanding: 101,630,713 (~0.02% of outstanding float)
• Securities Origin: Acquired via cash exercise of stock options under a registered plan on November 2, 2026 (multiple tranches totaling 15,269 shares), alongside previously exercised options acquired between May 2024 and January 2026 (totaling 5,860 shares).

Context & Assessment

While the gross transaction size is substantial at over $20 million, Form 144 filings related to option exercises and standard director equity management are common for mature large-cap biopharma companies. The sale represents approximately 0.02% of total shares outstanding and reflects structured option exercises rather than an unexpected divestment of core holdings.